Seeking Alpha

Aegerion Pharmaceuticals (AEGR 12.1%) is flying this morning after Capstone initiates the shares...

Aegerion Pharmaceuticals (AEGR 12.1%) is flying this morning after Capstone initiates the shares with a Buy. The coverage comes on the back of last week's initiation at Overweight by JPMorgan, and just ahead of an FDA advisory meeting scheduled for October 17 - 18 to debate the risks and benefits of AEGR's experimental drug Lomitapide NDA, for the treatment of homozygous familial hypercholesterolemia. The advisory panel recommendations often heavily influence FDA approval decisions.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|